Compare Eli Lilly And Co (LLY) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while YieldMax TSLA Option Income Strategy ETF trades at $22.45 (market cap $697.51M). The key difference: Eli Lilly And Co is far larger — about 1491× YieldMax TSLA Option Income Strategy ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while YieldMax TSLA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and YieldMax TSLA Option Income Strategy ETF for 43 Days on average.
| LLY | TSLY | |
|---|---|---|
Market Cap | $1.04T | $697.51M |
Volume | 3,064,878 | 338,271 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.28K | $43.35 |
52-Week Low | $799.57 | $20.49 |
Typical Hold Time | 93 Days | 43 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
TSLY trades at $22.45, down 0.66% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent analysis highlights concerns about missing Tesla's upside potential. Support levels cluster around $22 with resistance at $23-24, while RSI indicators remain neutral.
The outlook remains mixed with high yield appeal balanced against structural limitations in capturing Tesla's gains. Key risks include Tesla's volatility regime changes and the ETF's option income strategy constraints. Recent analyst downgrades to Hold reflect diminished upside capture potential amid Tesla's extended capex cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
